Cocrystal Pharma Inc.
Cocrystal Pharma, Inc. (Nasdaq: COCP) is a clinical-stage company developing novel, potent, broad-spectrum antiviral therapeutics to combat some of the most serious diseases facing humanity: coronaviruses (including SARS-CoV-2 and variants), pandemic and seasonal influenza, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs with high barriers to resistance.
Nasdaq: COCP
IR Website: https://ir.cocrystalpharma.com/
Headquarters: Bothell, WA
Content provided by Cocrystal Pharma on 3/6/22.
TALK TO MANAGEMENT
The Cocrystal Pharma management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Summary
Cocrystal Pharma, Inc. (Nasdaq: COCP) is a clinical-stage company developing novel, potent, broad-spectrum antiviral therapeutics to combat some of the most serious diseases facing humanity: coronaviruses (including SARS-CoV-2 and variants), pandemic and seasonal influenza, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs with high barriers to resistance. Highlights include:
-
In its COVID-19 program, the Company plans to initiate 2 Phase 1 trials in 2022 with novel protease inhibitors: one with an orally administered candidate and the other with an inhalation/pulmonary candidate. These candidates are specifically designed to block viral replication to be effective against COVID-19, its variants and other coronaviruses.
-
In its influenza programs, Cocrystal recently began enrolling subjects in a Phase 1 trial for treatment of pandemic and seasonal influenza A. Cocrystal also has an exclusive worldwide agreement with Merck for influenza A/B therapeutic. The company views this collaboration as a validation of its drug discovery platform technology in a transaction with potential of up to $156 million in milestone payments plus royalties on sales of drugs related to this program.
-
Cocrystal reported more than $61 million in cash at September 30, 2021, and has a cost-efficient business model and clean capital structure.
Investor Presentation
Recent News
Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344
Mar 10, 2022
Cocrystal Pharma to Participate in Upcoming Investment Conferences
Mar 3, 2022
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program
Jan 27, 2022
Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205
Jan 6, 2022
Cocrystal Pharma to Present at the H.C. Wainwright BioConnect Virtual Conference
Jan 4, 2022
Cocrystal Pharma’s COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant
Dec 22, 2021
Management Overview
Sam Lee, PhD
Interim Co-Chief Executive Officer and President
Dr. Sam Lee has over 25 years of anti-infective drug discovery research experience. Prior to Cocrystal, he managed anti-infective drug discovery projects for eight years at Icos Corporation (Nasdaq: ICOS). At Icos, Dr. Lee was responsible for incorporating protein crystallography and structural screening technologies into Icos research and played a key role for developing phosphoinositide 3-kinase (PI3K) delta inhibitors, which ultimately yielded an FDA approved product. He received his Ph.D. in Biological Sciences from the University of Notre Dame, and completed postdoctoral training in viral biochemistry with Dr. I. R. Lehman at Stanford University. While at Stanford, Dr. Lee founded and was CEO of Viral Assays in Cupertino, CA.
James J. Martin
Interim Co-Chief Executive Officer and Chief Financial Officer
Mr. James Martin has over 25 years of finance and management experience including providing financial leadership to commercial-stage, publicly traded health science companies. Prior to Cocrystal, Mr. Martin served as the Chief Financial Officer of Motus GI (Nasdaq: MOTS), a medical device company. From September 2014 to November 2016 he served as the Chief Financial Officer of VBI Vaccines, Inc. (formerly SciVac Therapeutics, Inc.) (Nasdaq: VBIV), a pharmaceutical development and manufacturing company. From April 2014 to September 2015, Mr. Martin served as Chief Financial Officer of Vapor Corp, Inc. (Nasdaq: VPCO), a vaporizer retail and wholesale company. From January 2011 to October 2013, Mr. Martin served as Chief Financial Officer of SafeStitch prior to its merger with TransEnterix, Inc. (NYSE: TRXC). Mr. Martin also serves as the Chief Financial Officer of Non-Invasive Monitoring Systems, Inc. (OTC Pink: NIMU), a company marketing non-invasive medical devices. Mr. Martin holds an undergraduate degree in business administration and an MBA from Barry University in Miami. He is a Certified Public Accountant.
Risks & Disclosures
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
Cocrystal Pharma Inc. (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2i digital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
B2I DIGITAL, Inc. is a marketing sponsor of the Roth 34th Annual Roth Conference. B2I DIGITAL, Inc. is not an affiliate of Roth Capital Partners, LLC (“Roth”) and is not authorized to represent or act on behalf of Roth ,in any capacity. Roth has not reviewed and approved the content contained on the b2idigital.com website.
